The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review [0.03%]
Ioannis Ntanasis-Stathopoulos,Sotirios Manganas,Charalampos Filippatos et al.
Ioannis Ntanasis-Stathopoulos et al.
Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can ...
Kenneth I Ataga
Kenneth I Ataga
Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. In...
Somatic Mutations and Mutation Burden Predict Treatment Response and Survival in Adult Acquired Pure Red Cell Aplasia [0.03%]
Liyan Yang,Huiqin Zhang,Yansong Wei et al.
Liyan Yang et al.
Immunosuppressive therapy (IST) is the standard treatment for acquired pure red cell aplasia (aPRCA), but predictors of treatment response and long-term prognosis remain unclear. The clinical significance of somatic mutations in aPRCA is no...
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia [0.03%]
Matteo Piccini,Naseema Gangat,Francesco Mannelli et al.
Matteo Piccini et al.
Dana Lewis,Thomas Lofaro,Laura Fraser et al.
Dana Lewis et al.
Case Reports
American journal of hematology. 2026 Mar 31. DOI:10.1002/ajh.70306 2026
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis [0.03%]
序贯免疫治疗失败后塞利尤方联合硼替佐米地塞米松治疗五线复发难治多发性骨髓瘤的疗效分析：一项多中心研究
Maximilian Al-Bazaz,Winfried Alsdorf,Lisa Leypoldt et al.
Maximilian Al-Bazaz et al.
Patients with relapsed/refractory multiple myeloma (RRMM) who are penta-drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, face a dismal prognosis, particul...
Distinctive Molecular Risk Factors Between MDS and MDS/AML Defined by ICC [0.03%]
ICC定义的MDS和MDS/AML之间的分子风险因素区别
Ting-Juan Zhang,Yang-Jing Zhao,Zi-Jun Xu et al.
Ting-Juan Zhang et al.
Myelodysplastic syndromes/neoplasms (MDS) represent a heterogeneous group of clonal hematopoietic stem cell diseases with high risks of acute myeloid leukemia (AML) transformation. To emphasize the characteristics of AML transformation, the...
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex [0.03%]
种族、族裔和性别对骨髓衰竭性疾病临床特征、遗传背景及病理变化的影响
Nancy Gillis,Christelle Colin-Leitzinger,Yi-Han Tang et al.
Nancy Gillis et al.
The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study-a prospectiv...
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and Sales [0.03%]
美国30年的经典血液学药物：批准，成本和销售额
Lucas T Go,Lewis T Go,Michelle A Elliott et al.
Lucas T Go et al.
Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review [0.03%]
血液系统恶性肿瘤中进行性多灶性白质脑病的临床特征和预后因素：意大利血液学研究联合会的一项回顾性分析
Davide Facchinelli,Linda Mazzai,Francesco Marchesi et al.
Davide Facchinelli et al.